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Rationale Engraftment and survival of transplanted stem or stromal cells in the microenvironment of host tissues may be im-
proved by combining such cells with scaffolds to delay apoptosis and enhance regenerative properties.
Aims We examined whether poly(lactic-co-glycolic acid) pharmacologically active microcarriers (PAMs) releasing vascular
endothelial growth factor (VEGF) enhance survival, differentiation, and angiogenesis of adipose tissue-mesenchymal
stromal cells (AT-MSCs). We analysed the efficacy of transplanted AT-MSCs conjugated with PAMs in a murine model
of acute myocardial infarction (AMI).
Methods
and results
We used fibronectin-coated (empty) PAMs or VEGF-releasing PAMs covered with murine AT-MSCs. Twelve-month-
old C57 mice underwent coronary artery ligation to induce AMI, and were randomized into five treatment groups: AMI
control (saline 20 mL, n ¼ 7), AMI followed by intramyocardial injection with AT-MSCs (2.5 × 105 cells/20 mL, n ¼ 5),
or concentrated medium (CM) from AT-MSCs (20 mL, n ¼ 8), or AT-MSCs (2.5 × 105 cells/20 mL) conjugated with
empty PAMs (n ¼ 7), or VEGF-releasing PAMs (n ¼ 8). Sham-operated mice (n ¼ 7) were used as controls. VEGF-re-
leasing PAMs increased proliferation and angiogenic potential of AT-MSCs, but did not impact their osteogenic or adi-
pogenic differentiation. AT-MSCs conjugated with VEGF-releasing PAMs inhibited apoptosis, decreased fibrosis,
increased arteriogenesis and the number of cardiac-resident Ki-67 positive cells, and improved myocardial fractional
shortening compared with AT-MSCs alone when transplanted into the infarcted hearts of C57 mice. With the excep-
tion of fractional shortening, all such effects of AT-MSCs conjugated with VEGF-PAMs were paralleled by the injection
of CM.
Conclusions AT-MSCs conjugated with VEGF-releasing PAMs exert paracrine effects that may have therapeutic applications.
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1. Introduction
Coronary artery disease and peripheral arterial disease are the major
causes of morbidity and mortality.1 While collateral vessel formation
as an alternative pathway for blood supply occurs in some of these pa-
tients, vascular networks adequate to compensate for the loss of the
original blood supply are formed infrequently and insufficiently. Such
patients might benefit from therapies that accelerate natural processes
of postnatal collateral vessel formation, an approach referred to as
therapeutic angiogenesis. On the other hand, recent reports have indi-
cated that the adult heart is self-healing and self-renewing since con-
taining a pool of resident cardiac stem/progenitor cells that are
capable of differentiating into new blood vessels or into new myo-
cytes.2 This suggests the opportunity to complement exogenous
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stem cell therapy by inducing endogenous cardiac cells to migrate, dif-
ferentiate, and proliferate in situ, thereby replacing lost endothelial cells
and cardiomyocytes. However, major obstacles in such approach are
the difficulty in engraftment and survival of transplanted stem cells in
the harmful microenvironment of the host tissue, and the difficulty in
stimulating recruitment of endogenous stem cells into the ischaemic
tissue.
To address these issues, there has been increasing focus on develop-
ment of novel biomaterials, including pharmacologically active micro-
spheres (PAMs) that allow in situ prolonged/controlled growth factor
delivery and cell adhesion to their surface functionalized with extracel-
lular matrix molecules.3,4 The combination of stem cells, PAMs and, in
further addition, growth factors may enhance the efficacy of cell ther-
apy in several ways: by mobilizing endogenous stem/progenitor cells in
vivo; by promoting cell proliferation and differentiation; and by aug-
menting cell engraftment and survival in the injured myocardium. Mes-
enchymal stromal cells (MSCs) are a population of regenerative cells
derived from the bone marrow or the adipose tissue (AT), which con-
tain a population of adult multipotent mesenchymal stem cells that can
regenerate damaged cardiovascular tissues.5 AT-MSCs are attractive
for regenerative medicine since they have strong paracrine properties,
as they are capable of secreting angiogenic factors such as vascular
endothelial growth factor (VEGF), which is a master regulator of angio-
genesis,6 hepatocyte growth factor (HGF), and fibroblast growth factor
(FGF); and are therefore expected to synergize with PAMs in modulat-
ing the arterial response to ischaemia or in inducing mobilization and
commitment of resident cardiac stem cells.
On this basis, we examined whether PAMs functionalized with fibro-
nectin and releasing VEGF enhance survival, growth, differentiation, and
angiogenesis of AT-MSCs compared with AT-MSCs alone. We also
analysed their therapeutic efficacy in a murine model of acute myocar-
dial infarction (AMI).
2. Methods
2.1 Animal care
All procedures were approved by the Chieti Institutional Ethics Committee
for animal research. All studies complied with the guidelines from Directive
2010/63/EU of the European Parliament on the protection of animals used
for scientific purposes or the NIH guidelines.
2.2 Isolation of mesenchymal stromal cells, cell
culture, and cell conjugation with PAMs
For our in vivo studies, we used a total number of 45 recipients animals
(12-month-old male C57/BL6 (C57) mice) and 12-month-old donors
male transgenic mice expressing green fluorescent protein (GFP) (Charles
River Laboratories, Calco, Lecco, Italy). For the isolation of MSCs, mice
were anaesthetized by inhalation of 2–5% isofluorane in oxygen, and eutha-
nized. Adequate level of anaesthesia was monitored by the lack of palpebral
and toe pinch reflexes. AT-MSCs were isolated from the peri-epididymal
visceral adipose tissue of C57 and GFP-expressing mice7 selected on the
basis of their adherence to plastic. AT-MSCs were cultured for up to three
passages and characterized for the expression of markers for mesenchymal
stem cells, endothelial cells, pericytes, fibroblasts, smooth muscle cells, and
monocyte/macrophages. Passage 3 cells were used for transplantation in
the in vivo experiments. Before injection, the GFP+ AT-MSCs were incu-
bated with 4′,6-diamidino-2-phenylindole (DAPI) (50 mmol/L) at 378C
for 15 min and re-suspended in phosphate-buffered saline (PBS).
Poly(lactic-co-glycolic acid) (PLGA)-microspheres of an average diameter
of 60 mm containing or not VEGF were prepared using an emulsion solvent
extraction–evaporation process previously described.8,9 Microspheres
were functionalized with fibronectin to obtain empty PAMs, as previously
described.8 For cell attachment to PAMs, 0.5 mg of empty or VEGF165-
releasing PAMs were incubated with 1 × 105 AT-MSCs. The percentage
of PAMs bound to the cells was evaluated by counting under optic micros-
copy. Murine AT-MSCs alone or conjugated with empty or VEGF-releasing
PAMs were characterized for their resistance to H2O2-induced apoptosis.
Detailed methods are described in the Supplementary material online.
2.3 Cell proliferation assays
Murine AT-MSCs (1 × 103 cells/cm2) from 12-month-old male C57 (n ¼ 4
mice per group), alone or conjugated with empty or VEGF-releasing PAMs
were plated onto a 96-well plate and counted daily from day 0 to day 21. At
each time point, the population doubling time was calculated by using the
following equation: t ¼ (log10[N/N0] × 3.33), where N is the total number
of cells and N0 is the number of seeded cells.
2.4 Osteogenic, adipogenic, and myogenic
differentiation assays
For the osteogenic, adipogenic, and myogenic differentiation analyses, we
examined Alizarin Red S staining, Oil-Red-O staining, or expression of
the myogenic markers cardiac actin and/or smooth muscle alpha-actin, re-
spectively, in AT-MSCs from 12-month-old male C57 (n ¼ 4 mice per
group), alone or conjugated with empty or VEGF-releasing PAMs, cultured
in specific differentiation media. Detailed methods are described in the
Supplementary material online.
2.5 Tube formation assays
For tube formation assays, AT-MSCs (alone or conjugated with empty or
VEGF-releasing PAMs) were plated on Matrigel for 24 h, then analysed
for tube areas, tube length, and tube number. Detailed methods are
described in the Supplementary material online.
2.6 Kinetics of VEGF and HGF release
At different time points after the change of fresh medium (from day 0 to day
21), supernatants were collected from AT-MSCs from 12-month-old male
C57, alone or conjugated with empty or VEGF-releasing PAMs. We ana-
lysed the concentration of murine VEGF and HGF in the supernatants by
using an enzyme-linked immunosorbent assay (ELISA; Quantikine Murine
VEGF and HGF Immunoassay, R&D Systems, Minneapolis, MN, USA).
Detailed methods are described in the Supplementary material online.
2.7 Induction of acute myocardial infarction,
treatments, and functional evaluation
AMIs were produced in adult C57 mice (12 months old, weighing 25–30 g)
irrespective of sex, by permanently ligating the left anterior descending
(LAD) coronary artery, as described in detail in the Supplementary material
online. Mice were randomly assigned to receive a single dose of one of the
following treatments 5 min after LAD ligation: (a) allogeneic DAPI+/GFP+
AT-MSCs (from 12-month-old GFP male mice) (2.5 × 105 cells/20 mL, n ¼
5); (b) concentrated medium (CM) from AT-MSCs (20 mL, n ¼ 8); or (c)
allogeneic DAPI+/GFP+ AT-MSCs (2.5 × 105 cells/20 mL) conjugated
with empty PAMs (n ¼ 7); or (d) allogeneic DAPI+/GFP+ AT-MSCs
(2.5 × 105 cells/20 mL) conjugated with VEGF-releasing PAMs (n ¼ 8);
(e) PBS (20 mL), as a non-cellular control (n ¼ 7). Each treatment was ad-
ministered via five intramyocardial injections in the anterior and posterior
infarct border zones of the ischaemic myocardium. Seven control mice
underwent a sham operation followed by PBS injections. In preliminary ex-
periments, we tested escalating doses of AT-MSCs by injecting mice in the
peri-infarct area with a single dose (20 mL volume divided into five injec-
tions of 4 mL each) of one of the following cell concentrations: 1 × 105,
1.5 × 105, 2.0 × 105, 2.5 × 105, 5.0 × 105, or 7.5 × 105. In those experi-
ments, we found that the maximum cell dosage compatible with mouse
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survival was 2.5 × 105 cells. After the surgical procedure, animals were
monitored every 24 h for 1 week, for the absence or presence of sign of
pain, distress, or discomfort. Animals received standard postoperative
care and returned to the laboratory 3 weeks later for echocardiography
analyses.
To assess the functional effects of each cell therapy, investigators blinded
to the treatment groups measured left ventricular end-systolic diameter
(LVESD), left ventricular end-diastolic diameter (LVEDD), and left ventricu-
lar fractional shortening (FS) 1 week before coronary artery ligation and at
7 and 21 days after the procedure by using a portable ultrasound apparatus
(Esaote, Genova, Italy) equipped with a 21-MHz linear probe. After the last
assessment of myocardial function, the mice were euthanized, and their
hearts were excised for histologic examination. Detailed methods are de-
scribed in the Supplementary material online.
2.8 Histologic evaluation of fibrosis, arteriolar
density, cell proliferation, and cell engraftment
rates
The excised hearts were transversely cut to obtain 15 sections (5 mm thick
each): 5 from the base of the ventricles, 5 from the middle of the ventricles,
and 5 from the apex. For each set of five sections, two were embedded in
paraffin and three were embedded in Tissue-Tekw OCT Compound me-
dium. All histologic sections were analysed in a blinded fashion. Fibrotic
areas were detected in the paraffin-embedded sections with haematoxylin
and eosin staining. Arteriolar density and cellular proliferation were deter-
mined by immunofluorescenly staining the OCT-embedded tissue sections
with cyanine 3- or phycoerythrin-conjugated rabbit IgG against alpha-
smooth muscle actin or Ki-67 (Sigma-Aldrich, St Louis, MO, USA), res-
pectively. The number and distribution of AT-MSCs alone or AT-MSCs
conjugated with empty PAMs or with VEGF-releasing PAMs were
determined by counting the GFP+/DAPI+ cells. The number and location
of smooth muscle alpha-actin-positive cells were determined by counting
cells positive for Cy3. Detailed methods are described in the Supplemen-
tary material online.
2.9 Enzyme-linked immunosorbent assay for
VEGF
Concentrations of VEGF in frozen heart tissues in each experimental group
were determined by ELISA (quantikine murine VEGF Immunoassay, R&D
System, Minneapolis, MN, USA). A standard curve was prepared from
nine VEGF dilutions. The lower limit of sensitivity was 8.4 pg/mL. The over-
all inter-assay and intra-assay coefficients of variation were ,10%. In each
well, total cellular proteins were measured with a bicinchoninic acid assay
(Pierce, Rockford, IL, USA). The VEGF content was normalized to cell
protein values.
2.10 Western blots
Total proteins from AT-MSCs or from heart tissues in each experimental
group were isolated and analysed for the expression of the following mar-
kers: (i) cardiac actin, (ii) collagen type III, (iii) caspase-3, or (iv) cleaved
caspase-3. Detailed methods are described in the Supplementary material
online.
2.11 Statistical analysis
Within each of the six treatment groups, the differences between baseline
and week 1 or 3 in FS, L-VEDD, and L-VESD were evaluated using a paired
t-test. To evaluate the differences in FS, L-VEDD, and L-LESD change across
groups, we used one-way ANOVA with Scheffe´’s multiple contrasts, con-
firmed using ANCOVA adjusting for baseline values, to compare the
mean differences between baseline and week 1 or 3. Statistical significance
Figure 1 Left ventricular FS 1 week and 3 weeks after AMI and intramyocardial injection of AT-MSCs with or without conjugation with PLGA micro-
spheres. Changes in FS in C57BL/6 mice that underwent a sham operation plus PBS injections (sham + PBS) or coronary artery ligation to induce AMI
plus injections of PBS (n ¼ 7 mice), or CM (n ¼ 8 mice) from AT-MSCs, or AT-MSCs only (n ¼ 5 mice), or AT-MSCs conjugated with empty micro-
spheres (n ¼ 7 mice) or VEGF-releasing PAMs (n ¼ 8 mice). Box-plot graph showing the median FS for each study group at baseline (1 week before
coronary artery ligation) and at 1 week and 3 weeks after intervention; for each study group at each time point, the graph shows the median, 25 and 75%
percentiles, minimum, and maximum values. *P, 0.05 vs. baseline; aP, 0.05 vs. sham + PBS; bP, 0.05 vs. AMI + PBS; cP, 0.05 vs. AMI + CM;
dP, 0.05 vs. AMI + MSCs; eP, 0.05 vs. AMI + MSCs + ePAM (one-way ANOVA with Scheffe correction, confirmed with ANCOVA adjusting for
baseline values). ePAM, empty PAMs; vPAM, VEGF-releasing PAMs; AT-MSCs, adipose tissue-derived mesenchymal stromal cells.
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was defined as a two-sided P-value ,0.05 for all analyses, which were per-
formed using Stata 13.1 (Stata Corp., College Station, TX, 2013).
3. Results
3.1 In vivo transplantation of AT-MSCs
conjugated with VEGF-releasing
microspheres improved cardiac function in a
murine model of AMI
Given that AT-MSCs conjugated with VEGF-releasing PAMs showed in
vitro evidence of decreased apoptosis (see Supplementary material on-
line, Figure S1), increased angiogenic potential (see Supplementary ma-
terial online, Figure S2), and VEGF production (see Supplementary
material online, Figure S3), we hypothesized that the delivery of
AT-MSCs in conjunction with such scaffolds would augment the en-
graftment and survival of AT-MSCs transplanted after AMI, and there-
fore enhance their regenerative properties. To examine the in vivo
effect of this novel combinatorial approach for myocardial repair,
AT-MSCs only, AT-MSCs conjugated with empty PAMs or with
VEGF-releasing PAMs, or PBS was injected into the infarcted hearts
of C57 mice by means of multiple intramuscular injections. Since para-
crine activity likely accounts for a substantial portion of the in vivo bene-
ficial effects produced by this cell type,10 we also included injections of
conditioned media from AT-MSCs as a non-cellular control. Left ven-
tricular FS (Figures 1 and 2) and diameters (Table 1) were measured be-
fore coronary ligation, 1 week and 3 weeks after ligation and
treatments. All mice with AMI, except those treated with AT-MSCs
conjugated with VEGF-releasing PAMs, showed a significant decrease
in FS at 1 and 3 weeks after coronary artery ligation, when compared
with baseline measurements and those from sham-operated mice. FS
was greater in post-AMI hearts at 1 and 3 weeks if treated with
AT-MSCs conjugated with VEGF-releasing PAMs than in post-AMI
hearts treated with AT-MSCs, AT-MSCs conjugated with empty
PAMs or PBS (Figures 1 and 2). Interestingly, inter-group and intra-
group comparisons of hearts before and after 1 week and 3 weeks
post-AMI + treatment revealed that CM did not exert similar positive
effects on LV function. Mice with AMI that were treated with AT-MSCs,
AT-MSCs conjugated with empty PAMs or PBS showed a significant in-
crease in LVEDD at 3 weeks after ligation, reflecting left ventricular dila-
tion (Table 1). However, transplantation of AT-MSCs conjugated with
VEGF-releasing PAMs and injection of CM significantly limited the
Figure 2 Left ventricular FS 1 week and 3 weeks after AMI and intramyocardial injection of AT-MSCs with or without conjugation with PLGA micro-
spheres. Individual changes in FS in C57BL/6 mice that underwent a sham operation plus PBS injections (sham + PBS) or coronary artery ligation to
induce AMI plus injections of PBS (n ¼ 7 mice), or CM (n ¼ 8 mice) from AT-MSCs, or AT-MSCs only (n ¼ 5 mice), or AT-MSCs conjugated with empty
microspheres (n ¼ 7 mice) or VEGF-releasing PAMs (n ¼ 8 mice). Values shown for baseline (1 week before coronary artery ligation) and for 1 week and
3 weeks after intervention. Results are presented as the mean+ SD. *P, 0.05 vs. baseline (paired t-test).
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increase in LVEDD induced by AMI (Table 1). Similar results were found
for LVESD.
No evidence of inflammation was observed at the injection site in
mice among the six groups, as indicated by the absence of cell infiltrates
on haematoxylin/eosin-stained slides of the infarcted hearts (Figure 4A–
F ). These results show that AT-MSCs reduce the post-AMI deterior-
ation of cardiac function and remodelling, and this cardioprotective
effect is mostly attributable to a paracrine effect of grafted cells.
3.2 In vivo transplantation of AT-MSCs
conjugated with VEGF-releasing
microspheres reduced post-ischaemic
fibrosis and improved arteriogenesis in a
murine model of AMI
Because neovascularization is believed to be essential for the functional
recovery of the heart after ischaemia, we examined arteriogenesis in
the infarcted hearts of C57 mice after cell therapy. To identify arter-
ioles, we used antibodies against smooth muscle cell alpha-actin to im-
munostain serial tissue sections from the mid-ventricle to the apex of
left ventricle, 21 days after treatment. Arteriolar density was markedly
increased in mice receiving either AT-MSCs conjugated with
VEGF-releasing PAMs or injection of CM when compared with those
that received PBS or AT-MSCs alone or AT-MSCs conjugated with
empty PAMs (Figure 3). Such results were paralleled by increased ex-
pression of VEGF in vivo. Indeed, in normal hearts (sham-operated
mice), the abundance of VEGF protein was much higher than that of
infarcted hearts treated with PBS. At 21 days after transplantation,
VEGF levels in the ischaemic transplanted area were much higher in
hearts injected with AT-MSCs conjugated with VEGF-releasing PAMs
or CM compared with those that received AT-MSCs alone or
AT-MSCs conjugated with empty PAMs (Table 2).
We also evaluated the effects of cell transplantation or CM injection
on cardiac remodelling. Formation of a collagen-rich scar was signifi-
cantly increased after AMI in mice treated with PBS or AT-MSCs alone
or AT-MSCs conjugated with empty PAMs (Figure 4B, D, E and G).
These effects were paralleled by increased expression of collagen
type III and decreased content of cardiac actin (Figure 4H–L). Trans-
plantation of AT-MSCs conjugated with VEGF-releasing PAMs or injec-
tion of CM decreased the extent of the area of fibrosis (Figure 4C and F )
and the expression of collagen type III (Figure 4G and I ), while increasing
the expression of cardiac actin (Figure 4H and L).
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Table 1 Effects of treatments on remodelling after the experimental AMI
Treatments Timing FS (%) P LVEDD (mm) P LVESD (mm) P
Sham + PBS Baseline (before sham) 50.6+3.9 3.1+0.5 1.9+0.5
1 1 week post-sham 50.0+5.2 3.2+0.8 1.7+0.7
3 weeks post-sham 48.7+4.4 3.0+0.5 1.6+0.5
D 1 week – baseline 20.6+2.6 0.1+0.3 20.1+0.3
D 3 weeks – baseline 21.9+3.1 20.1+0.1 20.2+0.8
AMI + PBS Baseline (before AMI) 50.0+2.2 3.7+0.4 2.4+0.6
2 1 week post-MI 19.0+7.2 4.3+0.7 3.4+0.9
3 weeks post-MI 17.1+4.2 5.3+1.1 4.5+1.1
D 1 week – baseline 231.0+6.6 *,A 0.6+0.9 1.1+0.4 *,A
D 3 weeks – baseline 232.8+4.0 *,A 1.5+1.4 *,A 2.0+1.6 *,A,D
AMI + CM Baseline (before AMI) 48.2+5.4 3.4+0.6 2.1+0.4
3 1 week post-MI 32.0+7.7 3.7+0.7 2.4+0.7
3 weeks post-MI 33.2+6.2 4.2+0.7 2.4+0.6
D 1 week – baseline 216.3+3.7 *,A B 0.4+0.9 0.4+1.1
D 3 weeks – baseline 215.0+10.0 *,A,B 0.7+1.1 0.3+0.7
AMI + MSCs Baseline (before AMI) 51.2+2.9 2.9+0.6 1.4+0.4
4 1 week post-MI 43.4+3.8 3.5+0.6 2.1+0.6
3 weeks post-MI 29.4+6.3 4.0+0.7 3.3+0.6
D 1 week – baseline 27.8+6.1 *,B 0.7+1.1 0.7+0.6
D 3 weeks – baseline 221.8+8.0 *,A 1.0+1.0 A 2.0+0.4 *,A,D
AMI + MSCs + ePAM Baseline (before AMI) 48.4+2.4 2.9+0.2 1.9+0.3
5 1 week post-MI 41.0+9.1 3.7+0.7 2.5+0.5
3 weeks post-MI 32.8+6.6 4.1+0.6 3.3+0.6
D 1 week – baseline 27.4+9.1 B 0.8+0.6* 0.5+0.6
D 3 weeks – baseline 215.6+7.0 *,A,B 1.1+0.7 *,A 1.3+0.6 *,A
AMI + MSCs + vPAM Baseline (before AMI) 48.7+2.1 2.3+0.6 1.9+0.7
6 1 week post-MI 54.1+1.6 3.6+0.5 2.6+0.5
3 weeks post-MI 52.0+3.6 3.3+0.5 2.2+0.6
D 1 week – baseline 5.3+2.3 *,B,C,D,E 1.2+0.3 *,A 0.5+0.8
D 3 weeks – baseline 3.3+3.6 *,B,C,D,E 0.9+0.7 * 0.3+0.5 B,C
All values are reported as means+ SDs.
All P-values have been computed using one-way ANOVA with Scheffe´’s correction, and confirmed using ANCOVA, adjusting for baseline values.
Sham, toracotomy + PBS injection; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; AT-MSCs, adipose tissue-mesenchymal stromal cells;
CM, conditioned medium; AMI, acute myocardial infarction; PAMs, pharmacologically active microspheres; VEGF, vascular endothelial growth factor.
*P, 0.05 vs. baseline; AP, 0.05 vs. sham; BP, 0.05 vs. AMI + PBS; CP, 0.05 vs. AMI + MSCs; DP, 0.05 vs. AMI + CM; EP, 0.05 vs. AMI + ePAM.
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3.3 In vivo transplantation of GFP1
AT-MSCs conjugated with VEGF-releasing
microspheres resulted in cell engraftment
into infarcted cardiac tissue and cellular
differentiation into vascular structures
To examine the engraftment and incorporation of transplanted GFP+/
DAPI+ AT-MSCs into vascular structures, we examined the long-term
engraftment of cells on transverse histologic sections of the infarcted
hearts. Cell retention 21 days after the transplantation of AT-MSCs
alone or of AT-MSCs conjugated with empty PAMs or VEGF-releasing
PAMs is shown in Figure 5. GFP+/DAPI+ cells were found in infarcted
hearts in the areas of GFP+/DAPI+ AT-MSC injections, whereas no
GFP+/DAPI+ cells were found in infarcted hearts that did not receive
cell delivery (Figure 5). At 21 days after transplantation, the number of
GFP+/DAPI+ AT-MSCs was much higher in hearts injected with
AT-MSCs conjugated with VEGF-releasing PAMs compared with those
that received AT-MSCs alone or AT-MSCs conjugated with empty
PAMs, indicating an increase in cell engraftment in the presence of
PAMs.
To further determine whether VEGF-releasing PAM conjugation af-
fects cell proliferation of the parenchyma surrounding the injection site,
we analysed the percentage of Ki-67-positive cells in the infarcted
hearts of cell-treated C57 mice. At 21 days after transplantation, C57
mice that received GFP+/DAPI+ AT-MSCs conjugated with
VEGF-releasing PAMs or injection of CM had a significantly higher per-
centage of Ki-67-positive cells than did those that received GFP+/
DAPI+ AT-MSCs alone or GFP+/DAPI+ AT-MSCs conjugated with
empty PAMs (Figure 6), indicating increased cell proliferation in the par-
enchyma surrounding the application site of GFP+/DAPI+ AT-MSCs
conjugated with VEGF-releasing PAMs or the injection of CM.
To determine whether transplanted cells integrate into the vascula-
ture directly or have a more indirect perivascular effect, we performed
morphometric analyses of infarcted hearts in cell-treated C57 mice
21 days after transplantation. We quantified the co-localization of
GFP expression with nuclei (DAPI) and smooth muscle alpha-actin. Im-
munofluorescence imaging of transverse heart sections immunostained
for smooth muscle alpha-actin revealed that GFP expression co-
localized with smooth muscle alpha-actin and DAPI staining in vascular
structures (Figure 7), suggesting the incorporation of GFP+/DAPI+
AT-MSCs into arterioles of the infarcted hearts. Co-localization of
GFP with DAPI and smooth muscle alpha-actin was much higher in
the infarcted hearts of C57 mice transplanted with AT-MSCs conju-
gated with VEGF-releasing PAMs than in those transplanted with
AT-MSCs alone or AT-MSCs conjugated with empty PAMs.
4. Discussion
This is the first demonstration that AT-MSCs conjugated with
VEGF-releasing PAMs results in increased proliferation, angiogenic dif-
ferentiation, and VEGF production, as well as decreased cell death
when compared with AT-MSCs alone or conjugated with empty
PAMs in vitro. Furthermore, in a murine model of AMI transplantation
of AT-MSCs conjugated with VEGF-releasing PAMs into the ischaemic
Figure 3 Arteriogenesis in hearts from C57 mice with AMI after the intramyocardial injection of AT-MSCs with or without conjugation with PLGA
microspheres. Histologic analysis of arteriogenesis is shown in the hearts of C57 mice that received injections of PBS (B, n ¼ 7 mice), or CM (n ¼ 8 mice)
from AT-MSCs (C), or AT-MSCs only (n ¼ 5 mice, D), or AT-MSCs conjugated with empty microspheres (n ¼ 7 mice, E) or VEGF-releasing PAMs
(n ¼ 8 mice, F). Control heart that received only PBS without coronary ligation (sham, n ¼ 7 mice) is shown in (A). The extent of arteriogenesis is shown
in (G). 8P, 0.05 AMI + PBS vs. sham + PBS, #P, 0.05 AMI + PBS vs. AMI + CM or AMI + AT-MSCs + VEGF-PAMs, §P, 0.05 AMI + AT-MSCs +
VEGF-PAMs vs. AMI + AT-MSCs or AMI + AT-MSCs + empty PAMs. N.S. not significant AMI + PBS vs. AMI + MSCs or AMI + CM vs. AMI +
AT-MSCs + VEGF PAM. Magnification¼60×. Scale bar: 50 mm.
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region improved post-AMI cardiac function and increased arteriogen-
esis. In these infarcted hearts in mice we provided evidence of cell en-
graftment and differentiation into vascular structures. Our findings
suggest that AT-MSCs conjugated with VEGF-releasing PAMs may
have therapeutic applications for use in treating patients with vascular
disease, particularly patients with a previous AMI.
Although encouraging results have been reported in cardiac cell
therapy studies, all reports concur that only few of the transplanted
cells survive in the hostile environment of the host tissue, such as
that occurring after an infarction, and integrate into the host myocar-
dium/myocardial scar.11 Transplanted cells quickly disappear from
the site of injection because they are removed by the blood flow and
degraded by specific enzymes in the extracellular microenvironment.11
Strategies using cells overexpressing pro-survival genes such as Akt,12
or co-transplantation with other cells such as endothelial cells,13 have
been investigated to improve cell survival in ischaemic models. All these
approaches have exploited the anti-apoptotic and proliferative proper-
ties of the VEGF signalling pathway, along with its capability of inducing
neovascularization in ischaemic conditions. Irrespective of the results
obtained, the amount of VEGF released by the cells in the ischaemic/in-
farcted area is not enough to promote sufficient protection of trans-
planted cells. On the other hand, strategies that employ viral vectors
aimed at conveying and releasing high amounts of VEGF at the site of
injection suffer from the several drawbacks of viral gene therapy, in-
cluding the potent induced immune response to the virus that limits
the duration of their effect and decrease cell engraftment.14
In the present study, we tried to overcome these limitations by em-
ploying PAMs releasing VEGF. Polymeric scaffolds that have been
tested previously for their ability to support transplanted cells have
been only marginally effective (reviewed in Ref. 4). In our study, we
used PAMs, which in general are capable of combining in situ controlled
drug delivery with implantation of cells adhered onto a biomaterial-
based microcarrier functionalized with extracellular matrix molecules.8
As a specific strategy, we used a microcarrier with a fibronectin-coated
surface developed to gradually release the encapsulated VEGF into the
injection area.8 The PAMs used in the present study are biocompatible
and biodegradable microspheres made of PLGA, a polymer approved
by the U.S. Food and Drug Administration and the European Medicinal
Figure 4 Structural analysis and myogenesis in hearts from C57 mice with AMI after the intramyocardial injection of AT-MSCs with or without con-
jugation with PLGA microspheres. Representative haematoxylin/eosin-stained cross-sections (A–G) or western analysis of cardiac actin and collagen
type III expression (H–I) of hearts of C57 mice that received injections of PBS (n ¼ 7 mice, B), or CM (n ¼ 8 mice, C ) from AT-MSCs, or AT-MSCs
only (n ¼ 5 mice, D), or AT-MSCs conjugated with empty microspheres (n ¼ 7 mice, E) or VEGF-releasing PAMs (n ¼ 8 mice, F ). Control heart that
received only PBS without coronary ligation (sham, n ¼ 7 mice) is shown in (A). The extent of fibrosis area is shown in (G). 88P, 0.01 sham + PBS vs.
AMI + PBS; ##P, 0.01 AMI + PBS vs. AMI + CM or AMI + AT-MSCs + VEGF-PAMs; §§P, 0.01 AMI + AT-MSCs + VEGF-PAMs vs. AMI + PBS or
AMI + AT-MSCs or AMI + AT-MSCs + empty PAMs or AMI + CM; §§P, 0.05 AMI + AT-MSCs + VEGF-PAMs vs. AMI + AT-MSCs or AMI +
AT-MSCs + empty PAMs; N.S. not significant AMI + PBS vs. AMI + MSCs or AMI + AT-MSCs + empty PAM. (J) Densitometric analysis of the protein
bands shown in (H) and (I ). Results are representative of three different experiments, and data are presented as the mean+ SD of n mice per group
(AMI + PBS, n ¼ 7 mice; AMI + CM, n ¼ 8 mice; AMI + AT-MSCs, n ¼ 5 mice; AMI + AT-MSCs + empty PAMs, n ¼ 7 mice; AMI + AT-MSCs +
VEGF-PAMs, n ¼ 8 mice). 88P, 0.01 sham + PBS vs. AMI + PBS; ##P, 0.01 AMI + PBS vs. AMI + CM or AMI + AT-MSCs + VEGF-PAMs; N.S.
not significant AMI + PBS vs. AMI + MSCs or AMI + AT-MSCs + empty PAM. Magnification¼40×. Scale bar: 50 mm. GAPDH levels were assessed
as a loading control.
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Agency for the formulation of implantable devices. These PAMs can mi-
mic, prolong, and amplify specific functions of adhered stem cells by
promoting their retention within the damaged area and enhancing their
survival, proliferation, and differentiation into cardiac and vascular cells,
all functions otherwise critically impaired in the delivery of cells alone.
This in vivo outcome further confirms previous in vitro results obtained
with PAMs releasing VEGF.9
In our approach, biomimetic PAMs have been used in conjunction
with AT-MSCs, which have per se strong paracrine properties, since
capable of secreting growth factors with pro-survival and angiogenic
properties, such as VEGF, HGF, and FGF.10 Our data thus reinforce
the concept that an additive or perhaps synergistic effect between
the release of VEGF, from the PAMs, and the release of other growth
factors, secreted by AT-MSCs, may exist, with a resulting improved
modulation of the angiogenic responses of the infarcted tissues.
AT-MSCs conjugated with VEGF-releasing PAMs indeed featured, after
transplantation into the infarcted tissue, a better formation of arterioles
than AT-MSCs alone or than AT-MSCs conjugated with empty PAMs.
This augmented pro-angiogenic property of AT-MSCs conjugated with
VEGF-releasing PAMs may reflect a decrease in the loss of vascular cells
due to the anti-apoptotic/anti-necrotic properties of VEGF. Alterna-
tively, the increased vascular density observed in infarcted tissues trea-
ted with AT-MSCs conjugated with VEGF-releasing PAMs may reflect a
response to the release of pro-angiogenic growth factors by AT-MSCs,
which was shown in our study to be potentiated by their conjugation
with VEGF-releasing PAMs. Our observations are in line with recent
Figure 5 Engraftments of AT-MSCs with or without conjugation with PLGA microspheres in the infarcted hearts. Representative fluorescence mi-
croscopy images of tissue sections showing the retention of DAPI/GFP+AT-MSCs (n ¼ 5 mice) (D) and (E and F) DAPI/GFP+AT-MSCs conjugated with
empty PAMs (n ¼ 7 mice) (E) or VEGF-releasing PAMs (n ¼ 8 mice) (F ) at the injection site 21 days after transplantation. Control hearts without cell
transplantation are shown in (A) (sham, n ¼ 7 mice), (B) (injection of PBS, n ¼ 7 mice) and (C) (injection of CM, n ¼ 8 mice). Quantitative data
showing the retention of DAPI/GFP+ AT-MSCs are shown in (G). Graph represents data combined from three independent experiments; results are
presented as the mean+ SD. 8P, 0.05 AMI + MSCs vs. AMI + MSCs + empty PAMs; §§P, 0.01 AMI + MSCs + empty PAMs vs. AMI +
AT-MSCs + VEGF-PAMs. Magnification¼60×. Scale bar: 50 mm.
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Table 2 Expression of murine VEGF as measured by
ELISA in various experimental conditions
Treatments Timing Murine VEGF
(pg/mL)
P
PBS – Undetectable –
Sham + PBS 3 weeks post-sham 2047+362
1
AMI + PBS 3 weeks post-MI 96+20 A
2
AMI + CM 3 weeks post-MI 991+107 A,B
3
AMI + MSCs 3 weeks post-MI 309+137 A,B
4
AMI + MSCs + ePAM 3 weeks post-MI 376+198 A,B
5
AMI + MSCs + vPAM 3 weeks post-MI 1379+261 A,B,C,D,E
6
All values are reported as means+ SDs.
Sham, toracotomy + PBS injection; AT-MSCs, adipose tissue-mesenchymal stromal
cells; CM, conditioned medium; AMI, acute myocardial infarction; PAMs,
pharmacologically active microspheres; VEGF, vascular endothelial growth factor.
AP, 0.05 vs. sham; BP, 0.05 vs. AMI + PBS; CP, 0.05 vs. AMI + MSCs; DP, 0.05
vs. AMI + CM; EP, 0.05 vs. AMI + ePAM.
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data in the literature showing that VEGF-releasing PAMs enhance
AT-MSCs survival, most likely through either the activation of pro-
survival kinases, such as the ERK 1/2 pathway, and Bcl-2-dependent me-
chanisms.8 Further studies are needed to assess the role of all of the
angiogenic factors secreted by AT-MSCs and assess their individual
and/or combined effects on endothelial cell proliferation and differen-
tiation into microvessels.
We also observed that the transplantation of AT-MSCs conjugated
with VEGF-releasing PAMs resulted in cell engraftment into infarcted
tissues and into cellular differentiation or integration into vascular
structures, as shown by the proliferation of these cells and their co-
localization with nuclei and smooth muscle cells. In vitro studies have
shown that PAMs releasing VEGF stimulate ADSCs differentiation to-
wards a cardiomyogenic lineage.9 However, it is not clear whether this
co-localization and concomitant increase in arteriogenesis resulted
from the fusion of transplanted cells with native vasculature (and pos-
sibly a vascular rescue due to decreased cell death), the directed differ-
entiation of transplanted cells, or the paracrine secretion of
pro-angiogenic growth factors by the transplanted cells in vivo. Distin-
guishing among these possibilities requires further investigation and
may lead to further refinement of our strategies to favour stem cell im-
plantation in the future.
The complexity of angiogenesis by itself suggests the combination
of cells and growth factors as a better strategy than using cells alone.
In our study, we demonstrate that conditioned medium (CM) is suf-
ficient to reproduce the effects of AT-MSCs conjugated with
VEGF-releasing PAMs on most endpoints here investigated.
However, AT-MSCs conjugated with VEGF-releasing PAM trans-
plantation exerted a superior therapeutic potential compared with
CM injection in terms of improvement of post-infarction cardiac
function. This superiority of AT-MSCs conjugated with
VEGF-releasing PAMs can be attributed at least in part to the ability
of AT-MSCs and PAMs to stabilize and support the formation of vas-
cular networks. The enhanced reconstruction of supporting micro-
vasculature that is functional to the improvement of cardiac
performance, as obtained with the use of transplanted AT-MSCs
conjugated with VEGF-releasing PAMs rather than of growth factors
only, may represent one important reason for continuing to pursue
cell-based therapies rather than therapies with cell-derived products
(CM). Observations from our study are in line with recent data show-
ing that CM derived from cardiospheres only modestly augmented
the percentage of Ki67+ cardiomyocytes, but did not improve
pump function in a murine model of AMI.15
Provided that our observations in a rodent model can be translated
into humans, our results suggest that the delivery of AT-MSCs and
VEGF-releasing PAMs is a potentially valuable novel strategy for
reducing stem cell apoptosis and loss in the transplanted area and for
enhancing the angiogenic response in the infarcted tissue. PLGA micro-
spheres are made-up of a biodegradable polymer, fully metabolized by
the organism. Such material has been already used in clinical trials for
treating gliomas,16 PLGA-based implantable devices are already ap-
proved by regulatory agencies, and PLGA sutures are widely used in
surgery. Thus, the use of such material has practical applicability already
at present for further testing.
Figure 6 Evaluation of proliferation by using the Ki-67 marker after myocardial infarction and cell transplantation. (A–F) Representative Ki-67-stained
cross-sections of heart of C57 mice that received injections of PBS (n ¼ 7 mice, B), or CM (n ¼ 8 mice, C) from AT-MSCs, or AT-MSCs only (n ¼ 5 mice,
D), or AT-MSCs conjugated with empty microspheres (n ¼ 7 mice, E) or VEGF-releasing PAMs (n ¼ 8 mice, F ). A section from a control heart without
coronary ligation is shown in (A) (sham, n ¼ 7 mice). (G) Quantitative data showing the percentage of red-fluorescent Ki-67-positive cells in relation to
the total number of nuclei. Graph represents data combined from three independent experiments; results are presented as the mean+ SD. ##P, 0.01
AMI + PBS vs. AMI + CM or AMI + AT-MSCs + empty PAMs or AMI + AT-MSCs + VEGF-PAMs; §§P, 0.01 AMI + AT-MSCs + VEGF-PAMs vs.
AMI + CM or AMI + AT-MSCs + empty PAMs. N.S. not significant sham + PBS vs. AMI + PBS. Magnification¼20×. Scale bar: 50 mm.
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Strengths of our study include the presence of appropriate multiple
controls—here provided by the injection of empty PAMs, AT-MSCs
alone, and CM—and the use of various analyses exploring mechanisms
of myocardial regeneration—i.e. arteriogenesis and the relevance of
paracrine effects—as well as the efficacy of cell transplantation in terms
of myocardial function. Such a complete demonstration was needed
because of the paucity of experimental data and appropriate controls
in the in vivo setting of previous studies.
In summary, VEGF-releasing PAMs may prolong and improve regen-
erative activities of stem cells, whether they are resident cardiac stem cells
(potentially—not investigated by us) or transplanted stem cells from ex-
ogenous sources (such as in our cases), in the healing processes of in-
farcted tissues. This system appears to maximize the biological effects
of stem cells through specifically targeting the injured area, and therefore
appears to be suited for potential clinical use and industrial applicability.
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